LXRX - Lexicon Pharma rallies 44% on Fast Track tag for LX9211 in diabetic neuropathic pain

Lexicon Pharmaceuticals (LXRX) soars 44% premarket after has receiving Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application. Lexicon is currently enrolling patients with diabetic neuropathic pain in a Phase 2 study of LX9211 and is preparing to initiate a second Phase 2 trial of LX9211 in post-herpetic neuralgia.Peripheral neuropathy is nerve damage caused by chronically high blood sugar and diabetes. It leads to numbness, loss of sensation, and sometimes pain in your feet, legs, or hands.

For further details see:

Lexicon Pharma rallies 44% on Fast Track tag for LX9211 in diabetic neuropathic pain